Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia: A randomised, heparin-controlled pilot study

Elisabetta Cofrancesco, Carla Boschetti, Patrizia Leonardi, Francesco Gianese, Michele Cortellaro

Research output: Contribution to journalArticlepeer-review

Abstract

Efficacy and safety of i.v. dermatan sulphate (DS) and heparin (H) in controlling laboratory alterations due to DIC were compared in 10 patients with acute leukaemia, in a prospective, randomised pilot study. The time courses of the coagulation and fibrinolysis markers for DIC were similar in the two treatment groups except for activated partial thromboplastin time and thrombin time, which were prolonged in the H but not in the DS group. Blood product support tended to be greater in the H than in the DS group. DS appears to be as effective as H in controlling thrombin production during leukaemic cytolysis and may represent a safer alternative to H in the management of DIC in acute leukaemia.

Original languageEnglish
Pages (from-to)65-75
Number of pages11
JournalThrombosis Research
Volume74
Issue number1
DOIs
Publication statusPublished - Apr 1 1994

Keywords

  • acute leukaemia
  • dermatan sulphate
  • DIC
  • heparin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Fingerprint Dive into the research topics of 'Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia: A randomised, heparin-controlled pilot study'. Together they form a unique fingerprint.

Cite this